Shuttle Pharmaceuticals, Inc. Awarded a New Patent for Dual Function HDAC Molecules for HDAC Inhibition and Ataxia Telangiectasia Mutated Activation for Cancer Treatment ...Middle East

ROCKVILLE, Md., Nov. 4, 2020 /PRNewswire/ -- Shuttle Pharmaceuticals, Inc (Shuttle Pharma) a clinical stage, Maryland-based, biopharmaceutical company developing new drugs for cancer treatment in combination with radiation therapy, was awarded patent number 10,745,352 by the U.S. Patent...

Read More Details
Finally We wish PressBee provided you with enough information of ( Shuttle Pharmaceuticals, Inc. Awarded a New Patent for Dual Function HDAC Molecules for HDAC Inhibition and Ataxia Telangiectasia Mutated Activation for Cancer Treatment )

Also on site :

• Japan starts deploying Osprey fleet at a new base to beef up southwestern defense
• South Africa seeks US trade deal after Trump’s 30% citrus tariff
• Josh O’Connor Goes Full Cowboy in ‘Rebuilding’ as Director Max Walker-Silverman Takes on Life After the Fires: ‘Loss Often Comes With Love’